Show simple item record

dc.contributor.authorLim, Sun-Young
dc.contributor.authorGuo, Zhiru
dc.contributor.authorLiu, Ping
dc.contributor.authorMcKay, Lindsay G A
dc.contributor.authorStorm, Nadia
dc.contributor.authorGriffiths, Anthony
dc.contributor.authorQu, Ming Da
dc.contributor.authorFinberg, Robert W.
dc.contributor.authorSomasundaran, Mohan
dc.contributor.authorWang, Jennifer P
dc.date.accessioned2024-03-08T21:46:42Z
dc.date.available2024-03-08T21:46:42Z
dc.date.issued2022-10-28
dc.identifier.citationLim SY, Guo Z, Liu P, McKay LGA, Storm N, Griffiths A, Qu MD, Finberg RW, Somasundaran M, Wang JP. Anti-SARS-CoV-2 Activity of Adamantanes In Vitro and in Animal Models of Infection. COVID. 2022 Nov;2(11):1551-1563. doi: 10.3390/covid2110111. Epub 2022 Oct 28. PMID: 37274537; PMCID: PMC10238102.en_US
dc.identifier.eissn2673-8112
dc.identifier.doi10.3390/covid2110111en_US
dc.identifier.pmid37274537
dc.identifier.urihttp://hdl.handle.net/20.500.14038/53146
dc.description.abstractCoronavirus disease 2019 (COVID-19) has had devastating effects worldwide, with particularly high morbidity and mortality in outbreaks on residential care facilities. Amantadine, originally licensed as an antiviral agent for therapy and prophylaxis against influenza A virus, has beneficial effects on patients with Parkinson's disease and is used for treatment of Parkinson's disease, multiple sclerosis, acquired brain injury, and various other neurological disorders. Recent observational data suggest an inverse relationship between the use of amantadine and COVID-19. Adamantanes, including amantadine and rimantadine, are reported to have in vitro activity against severe acute respiratory syndrome coronavirus (SARS-CoV) and, more recently, SARS-CoV-2. We hypothesized that adamantanes have antiviral activity against SARS-CoV-2, including variant strains. To assess the activity of adamantanes against SARS-CoV-2, we used in vitro and in vivo models of infection. We established that amantadine, rimantadine, and tromantadine inhibit the growth of SARS-CoV-2 in vitro in cultured human epithelial cells. While neither rimantadine nor amantadine reduces lung viral titers in mice infected with mouse-adapted SARS-CoV-2, rimantadine significantly reduces viral titers in the lungs in golden Syrian hamsters infected with SARS-CoV-2. In summary, rimantadine has antiviral activity against SARS-CoV-2 in human alveolar epithelial cells and in the hamster model of SARS-CoV-2 lung infection. The evaluation of amantadine or rimantadine in human randomized controlled trials can definitively address applications for the treatment or prevention of COVID-19.en_US
dc.language.isoenen_US
dc.relation.ispartofCOVIDen_US
dc.relation.urlhttps://doi.org/10.3390/covid2110111en_US
dc.rightsCopyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).en_US
dc.rightsAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectACE2-A549 cellsen_US
dc.subjectCOVID-19en_US
dc.subjectSARS-CoV-2en_US
dc.subjectamantadineen_US
dc.subjecthamsteren_US
dc.subjectrimantadineen_US
dc.titleAnti-SARS-CoV-2 Activity of Adamantanes In Vitro and in Animal Models of Infectionen_US
dc.typeJournal Articleen_US
dc.source.journaltitleCOVID
dc.source.volume2
dc.source.issue11
dc.source.beginpage1551
dc.source.endpage1563
dc.source.countryUnited States
dc.source.countrySwitzerland
dc.identifier.journalCOVID
refterms.dateFOA2024-03-08T21:46:44Z
dc.contributor.departmentBiochemistry and Molecular Biotechnologyen_US
dc.contributor.departmentMedicineen_US
dc.contributor.departmentMorningside Graduate School of Biomedical Sciencesen_US
dc.contributor.studentSun-Young Lim


Files in this item

Thumbnail
Name:
covid-02-00111.pdf
Size:
1.687Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Copyright: © 2022 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
Except where otherwise noted, this item's license is described as Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).